Literature DB >> 18474681

Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.

Sanna Kaivosaari1, Päivi Toivonen, Olli Aitio, Julius Sipilä, Mikko Koskinen, Jarmo S Salonen, Moshe Finel.   

Abstract

Medetomidine is a chiral imidazole derivate whose dextroenantiomer is pharmacologically active. The major metabolic pathway of dexmedetomidine [(+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] in humans is N-glucuronidation at the imidazolate nitrogens. We have purified the N3- and N1-glucuronides of dexmedetomidine, termed DG1 and DG2, respectively, according to their elution order in liquid chromatography and determined their structure by 1H nuclear magnetic resonance (NMR). Studying medetomidine glucuronidation by human liver microsomes (HLMs) and recombinant UDP glucuronosyltransferase (UGT) 1A4 indicated that another human UGT plays a major role in these activities. We now demonstrate that this enzyme is UGT2B10. HLMs catalyzed DG1 and DG2 formation, at a ratio of 3:1, with two-enzyme kinetics that contain both a high-affinity component, K(m1) values of 6.6 and 8.7 microM, and a low-affinity component, K(m2) values > 1 mM. The DG1/DG2 ratio in the case of UGT2B10 was lower, 1.4:1, whereas the substrate affinity for both reactions was high, K(m) values of 11 and 16 microM. UGT1A4 produced mainly DG1 (DG1/DG2 ratio of 6.6:1) at low substrate affinities, K(m) values above 0.6 mM, but superior expression-normalized V(max) values. Levomedetomidine [(-)-4-(R)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole] glucuronidation by HLMs yielded mostly the N3-glucuronide (LG1, structure determined by NMR), with monophasic kinetics and a K(m) value of 14 microM. The activity of UGT1A4 toward levomedetomide was low and generated both LG1 and LG2, whereas UGT2B10 exhibited relatively high activity and sharp regioselectivity, yielding only LG1, with a K(m) value of 7.4 microM. The results highlight the contribution of UGT2B10 to medetomidine glucuronidation and its potential importance for other N-glucuronidation reactions within the human liver.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474681     DOI: 10.1124/dmd.108.021709

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

1.  Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing.

Authors:  Adrien Labriet; Eric P Allain; Michèle Rouleau; Yannick Audet-Delage; Lyne Villeneuve; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2018-02-09       Impact factor: 3.922

2.  Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.

Authors:  Nenad Manevski; Mika Kurkela; Camilla Höglund; Timo Mauriala; Michael H Court; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2009-12-10       Impact factor: 3.922

3.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

4.  Dexmedetomidine pharmacokinetics in the obese.

Authors:  Luis I Cortínez; Brian J Anderson; Nick H G Holford; Valentina Puga; Natalia de la Fuente; Hernán Auad; Sandra Solari; Fidel A Allende; Mauricio Ibacache
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

5.  A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Authors:  Aleksandra K Greer; Centdrika R Dates; Athena Starlard-Davenport; Vineetha K Edavana; Stacie M Bratton; Ishwori B Dhakal; Moshe Finel; Susan A Kadlubar; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2014-06-10       Impact factor: 3.922

6.  Inhibition of the cardiac Na⁺ channel α-subunit Nav1.5 by propofol and dexmedetomidine.

Authors:  Carsten Stoetzer; Svenja Reuter; Thorben Doll; Nilufar Foadi; Florian Wegner; Andreas Leffler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-15       Impact factor: 3.000

7.  Proton nuclear magnetic resonance and pattern recognition analysis of liver extracts from rats under different anesthetics.

Authors:  Tomoyuki Tajima; Keiko Hirakawa; Hiroshi Kawaguchi; Atsuhiro Sakamoto
Journal:  BMC Med Imaging       Date:  2012-08-16       Impact factor: 1.930

8.  Population pharmacokinetics of dexmedetomidine in critically ill patients.

Authors:  Pyry Antti Välitalo; Tuula Ahtola-Sätilä; Andrew Wighton; Toni Sarapohja; Pasi Pohjanjousi; Chris Garratt
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

9.  Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent.

Authors:  Nenad Manevski; Johanna Troberg; Paolo Svaluto-Moreolo; Klaudyna Dziedzic; Jari Yli-Kauhaluoma; Moshe Finel
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

Review 10.  Interpatient variability in dexmedetomidine response: a survey of the literature.

Authors:  Samantha F Holliday; Sandra L Kane-Gill; Philip E Empey; Mitchell S Buckley; Pamela L Smithburger
Journal:  ScientificWorldJournal       Date:  2014-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.